The double burden of malnutrition in Mexican adolescents
| ISRCTN | ISRCTN65337024 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN65337024 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | Nil known |
| Sponsors | Universidad de Monterrey, Wageningen University & Research |
| Funders | Universidad de Monterrey (UDEM), Consejo Nacional de Ciencia y Tecnología (National Council of Science and Technology, Mexico) |
- Submission date
- 01/05/2020
- Registration date
- 15/06/2020
- Last edited
- 15/09/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Background and study aims
Major depressive disorder (MDD) and Iron deficiency anemia are two of the three main causes of disability among adolescents worldwide. Additionally, iron plays an important role in the synthesis of neurotransmitters (signaling chemicals found in the brain and nervous system) and in neurological development.
The aim of this study is to examine the association of anemia and iron deficiency with depressive symptoms and self-harm behavior in Mexican adolescent girls.
Who can participate?
Girls aged 12 to 19 years old, who live in urban areas in Northern Mexico
What does the study involve?
Participants will be assessed for anthropocentric measures, pubertal development, hemoglobin levels and iron status (from blood samples), as well as depressive symptoms and self-harm behavior.
What are the possible benefits and risks of participating?
Participants will receive a report of their nutritional status and iron status. At the end of the study participants receive nutritional recommendations and the opportunity to have a free psychological evaluation. This study is not thought to be associated with increased health risks. However, blood drawing occasionally can cause bruising.
Where is the study run from?
Universidad de Monterrey (Mexico)
When is the study starting and how long is it expected to run for?
From September 2018 to March 2019
Who is funding the study?
Universidad de Monterrey (Mexico)
Who is the main contact?
Dr Ana Carla Cepeda-Lopez
ana.cepeda@udem.edu
Contact information
Scientific
Av. Ignacio Morones Prieto 4500 poniente
Col. Jesús M. Garza
San Pedro Garza García
Nuevo León
San Pedro Garza García
66238
Mexico
 ORCID ID |
0000-0002-3935-3917 |
|---|---|
| Phone | +52 (81) 8215-1000 |
| ana.cepeda@udem.edu |
Study information
| Primary study design | Observational |
|---|---|
| Study design | Cross-sectional observational study |
| Secondary study design | Cross sectional study |
| Study type | Participant information sheet |
| Scientific title | Investigation of the iron status and presence of depressive symptoms and self-harm behavior, and the possible interaction of this association with the gut microbiota, intestinal inflammation and pubertal development in adolescent girls living in Mexico |
| Study acronym | DBM ADOL |
| Study objectives | Iron deficiency in Mexican adolescents may be associated with the presence of depressive symptoms and self-harm behavior. |
| Ethics approval(s) | Approved 04/07/2018, the Research Ethics Committee of the University of Monterrey (Av. Morones Prieto 4500 Pte, San Pedro Garza Gacia, Nuevo Leon, Mexico 66238; +52 (81) 8215 1212), ref: 04072018-CEI |
| Health condition(s) or problem(s) studied | Iron deficiency and depressive symptoms |
| Intervention | Adolescent girls aged 12 to 19 inclusive from public schools were recruited. Written consent was obtained from the adolescents and their parents. The assessment and samples were taken within one visit. Blood samples were drawn by a trained nurse or a technician in order to assess iron status (SF, BIS and sTfR), and inflammation (CRP, AGP) biomarkers. The serum samples were exported to Germany, where iron and inflammation biomarkers were measured using in-house sandwich enzyme-linked immunosorbent assay in the Vitmin Lab, Germany. The Six-item Kutcher Adolescent Depression Scale (6-KADS) (LeBlanc, et al., 2002) was used to identify if the adolescent has symptoms of depression. The 6-KADS was developed to assist in the public health and clinical identification of young people at risk for depression. |
| Intervention type | Other |
| Primary outcome measure(s) |
All outcome measures were assessed at a single timepoint. |
| Key secondary outcome measure(s) |
1. Anemia measured using a Hemocue 201+ portable photometer apparatus to assess hemoglobin in capillary blood |
| Completion date | 08/03/2019 |
Eligibility
| Participant type(s) | Healthy volunteer |
|---|---|
| Age group | Other |
| Sex | Female |
| Target sample size at registration | 450 |
| Total final enrolment | 408 |
| Key inclusion criteria | 1. Adolescent girls aged 12 to 19 inclusive attending public schools. 2. Written consent from the parents or legal guardians 3. Written consent from the adolescents 4. Considered to be in good health |
| Key exclusion criteria | 1. Diagnosis of chronic disease that may affect iron status. 2. History of major surgery in the last month (at the moment of recruitment). 3. Regular use of antibiotics. |
| Date of first enrolment | 04/09/2018 |
| Date of final enrolment | 08/03/2019 |
Locations
Countries of recruitment
- Mexico
Study participating centre
Col. Jesús M. Garza
San Pedro Garza García
Nuevo León, México
San Pedro Garza, Garcia
66238
Mexico
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Published as a supplement to the results publication |
| IPD sharing plan | The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication. Datasets will be shared under request with the reviewers for publication purposes. The use of the datasets generated during this study by a third party can be possible only if Universidad de Monterrey and Wageningen University agree. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 18/05/2022 | 15/09/2022 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
15/09/2022: Publication reference added.
20/05/2020: Trial’s existence confirmed by the Research Ethics Committee of the University of Monterrey.
